Proteasome Inhibitors and Patients

Slides:

Advertisements

Similar presentations

Richardson PG et al. Proc ASH 2013;Abstract 535.

Advertisements

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Mateos MV et al. Proc ASH 2013;Abstract 403.

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Diabetic Dyslipidemia in Practice

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Hot Off the Press: Changes in the Landscape of Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Innovations and Issues in Mantle Cell Lymphoma

Advanced NSCLC Without Actionable Mutations

Selecting Therapy for Relapsed/ Refractory Multiple Myeloma

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

What Do We Know About LDL-C?

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Therapy for Relapsed Multiple Myeloma

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

IL-17 Inhibitors in the Management of Psoriatic Disease

The Nurse View: Best Practices in Multiple Myeloma

How Can we Improve Outcomes for the Elderly Patient with AML?

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

VTE Treatment Conventional Approach

The Biology Behind BCL2 as a Target in Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Multiple Myeloma

Evaluating Next-Generation BTK Inhibitors

Navigating New Oral Treatment Algorithms in CLL

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Managing Adverse Events With New Oral Therapies in CLL

Immunotherapy for cSCC

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,

Personalized Therapy in Relapsed or Refractory CLL

When Is Biologic Therapy Appropriate for HS?

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Approaches in Newly Diagnosed Multiple Myeloma: When and What

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

What's New in Therapeutic Options for Moderate to Severe RA?

New Classes of Therapy in Multiple Myeloma

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

The Road to Quality Improvement in HER2-Positive Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

The Role of Maintenance Therapy in Multiple Myeloma

Are We Making Progress in the Management of Huntington Disease?

Therapy for Relapsed Multiple Myeloma

Update on the Management of Atopic Dermatitis

On the Cusp: New Approaches for Multiple Myeloma

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Third-Generation EGFR TKIs

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Real-World Evidence.

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Changing Paradigms in Relapsed/Refractory Indolent NHL

PCSK9 Inhibitors and Real-World Evidence

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Proteasome Inhibitors and Patients

RRMM Overview

Multiple Treatment Options Are Available for RRMM

Proteasome Inhibitors: Key Characteristics

ESMO Practice Guidelines: RRMM

Type of Relapse May Influence Treatment Decisions

Efficacy of Ixazomib in Patients With RRMM and High-Risk Cytogenetics: TOURMALINE-1 Trial

Choice of Proteasome Inhibitor at Relapse Depends on Multiple Factors

Patient Profile 1: Young and Fit

Prolonged Exposure to Proteasome Inhibitors Is Associated With Improved Outcomes

Duration of Exposure to IRd in the Phase 3 TOURMALINE-1 Trial

Weekly vs Twice Weekly Administration of Carfilzomib in RRMM: Phase 3 ARROW Trial

Bortezomib Maintenance Therapy Improves Depth of Response After ASCT

Ongoing Phase 3 Trials of Ixazomib as Maintenance Therapy

Patient Profile 2: Old and Frail

Safety Comparison of IRd vs Rd: Phase 3 TOURMALINE-1 Trial

Patient Profile 3: Comorbidities

Patient Profile 4: Disease-Related Factors

Selecting an Appropriate Treatment for the Patient With RRMM

Closing Remarks

Abbreviations

Abbreviations (cont)